Ethel Crowley

Learn More
BACKGROUND This phase I study assessed the maximum tolerated dose, dose-limiting toxicity (DLT) and pharmacokinetics of belinostat with carboplatin and paclitaxel and the anti-tumour activity of the combination in solid tumours. METHODS Cohorts of three to six patients were treated with escalating doses of belinostat administered intravenously once daily,(More)
BACKGROUND Although severe chronic kidney disease (CKD) is an independent predictor of mortality among patients with coronary artery disease, the impact of mild CKD on morbidity and mortality has not been fully defined. METHODS AND RESULTS Morbidity and mortality for the 3608 patients with multivessel coronary artery disease enrolled in the Bypass(More)
  • 1